AZD 1134

Drug Profile

AZD 1134

Latest Information Update: 31 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Serotonin 1B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 31 Mar 2004 Discontinued - Preclinical for Anxiety disorders in USA (unspecified route)
  • 31 Mar 2004 Discontinued - Preclinical for Depression in USA (unspecified route)
  • 02 Oct 2003 Data presented at the 16th Congress of the European College of Neuropsychopharmacology (ECNP-2003) have been added to the Affective and Anxiety disorders pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top